Haroon Shabbir

Mr. Haroon Shabbir

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2022 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
HSHaroon Shabbir
Haroon Shabbir
SSSajeel Saeed
Sajeel Saeed
MFMuhammad Farhan
Muhammad Farhan
KAKhawar Abbas
Khawar Abbas
EREbad Rehman
Ebad Rehman
JBJawad Basit
Jawad Basit
Poliomyelitis is a viral disease that causes acute paralysis, muscle weakness and autonomic dysfunction. It primarily affects children under the age of five. It is mainly transmitted via the feco-oral route, through contaminated water. As of the year 2022, Pakistan remains one of the two countries where polio is still endemic, the other being Afghanistan. Numerous myths and misconceptions regarding the polio vaccine, lack of awareness and proper governance, terrorism and difficult access to remote areas due to poor infrastructure are just some of the reasons why polio remains endemic in Pakistan to this day. Therefore, the government should take measures to ensure the safety and wellbeing of health care workers, as well as spread awareness regarding the importance of polio vaccines, while addressing the myths and misconception regarding said vaccines.

17 July 2023 in Cureus
Verified
Journal Article
Open access
PDF file
ZKZainab Z. Khan
Zainab Z. Khan
UAUsman Ahmed
Usman Ahmed
FSFaizan Shahzad
Faizan Shahzad
MAMuaz Ali
Muaz Ali
KTKashif Tousif
Kashif Tousif
HSHaroon Shabbir
Haroon Shabbir
Drugs that act on the calcitonin gene-related peptide (CGRP) pathway herald the dawn of a new era in the management of migraine headaches. The blockade of CGRP alleviates neural inflammation and has been associated with reduced pain sensitization. Zavegepant is a third-generation drug and is the first intranasal CGRP antagonist to be developed. This systematic review aims to assess the safety, efficacy, pharmacokinetics, and tolerability of Zavegepant as an abortive treatment for migraine. Studies that assessed the safety, tolerability, and efficacy of Zavegepant for migraine were identified through a systematic literature review of PubMed, Clinicaltrials.gov, and Cochrane databases in April 2023. Our systematic review yielded a total of six studies that fit our inclusion criteria. Of these, data from only two randomized control trials (RCTs) was homogenous; hence, forest plots of results pooled from the included studies were not reported. The included studies showed that Zavegepant is an efficacious and well-tolerated abortive treatment modality for episodic migraine in adult patients. Zavegepant showed safety and efficacy in migraine treatment according to various parameters throughout the six included studies. These parameters include adverse events, pharmacokinetic properties, CGRP inhibition, effect on blood pressure/electrocardiogram, pain freedom, and freedom from most bothersome symptoms.

18 August 2022 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SSSajeel Saeed
Sajeel Saeed
HSHaroon Shabbir
Haroon Shabbir
JBJawad Basit
Jawad Basit
EREbad Rehman
Ebad Rehman
Monkeypox is a vesicular, pustular illness caused by an orthopox virus. It has remained endemic to the Central and West African regions for the past four decades, with only a few outbreaks outside these regions. It is mainly transmitted by direct skin to skin with an infected individual who has developed pustules. Recently there have been major outbreaks in about fourteen countries of the world, and over nine hundred people have been infected. This short summary gives a review about the epidemiology, history, virulence, symptoms and prevention of Monkeypox, while addressing a major question that the general public has right now: “Will Monkeypox turn into the next global pandemic?”.